Contract Deobligations Alert — September 03, 2026

Walgreens secured a fully obligated, firm-fixed-price contract from the CDC for the ICATT program, awarded via full and open competition, signaling competitive merit and near-term revenue certainty of ~$96.9M annually.

The firm-fixed-price structure of Walgreens' $290.9M CDC contract carries medium execution risk; cost overruns could compress margins, especially given the service-oriented nature (NAICS 621999) with low technology content.

This single $290.9M contract represents 100% of the digest's total obligation, creating a concentration risk for Walgreens if the ICATT program faces budget cuts or re-compete loss.

Walgreens' competitive win in the CDC's ICATT program positions it for follow-on awards or expansions, given the program's stable funding trajectory for specialized medical support services.

The CDC's fully obligated $290.9M award to Walgreens under a competitive process underscores sustained demand for specialized medical support services, despite broader federal budget uncertainty.

{"entity" => "Walgreens Boots Alliance", "reason" => "The $290.9M CDC contract is material to near-term revenue but carries fixed-price execution risk and no defense diversification.", "trigger" => "Q2 2025 earnings call for cost management details; CDC FY2025 budget release for ICATT program funding levels"}

{"entity" => "CDC ICATT Program", "reason" => "This program is the sole source of the digest's largest contract; any budget cuts or re-compete announcements could materially impact Walgreens.", "trigger" => "FY2025-2026 appropriations bills; re-compete solicitation release"}